Rigel Pharmaceuticals, Inc

(NASDAQ:RIGL)

Latest On Rigel Pharmaceuticals, Inc (RIGL):

Date/Time Type Description Signal Details
2023-05-26 15:54 ESTNewsRigel Pharmaceuticals Shows Promise With Q1 Earnings: Tavalisse And Rezlidhia Drive GrowthN/A
2023-05-03 02:14 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.02, revenue of $26.07M beats by $2MN/A
2023-05-03 02:13 ESTNewsRigel Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-03 02:13 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q1 2023 Earnings Call TranscriptN/A
2023-05-02 01:42 ESTNewsRigel Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-27 09:21 ESTNewsRigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For ProfitabilityN/A
2023-04-04 02:31 ESTNewsRigel Pharma begun at neutral at Piper Sandler on value creation potentialN/A
2023-03-09 06:02 ESTNewsRigel Pharmaceuticals' Challenges Continue To Outweigh Potential UpsideN/A
2023-03-08 00:02 ESTNewsRigel Pharma, with beats on quarterly top and bottom lines, surges 19%N/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals GAAP EPS of $0.34 beats by $0.80, revenue of $120.24M beats by $27.04MN/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call TranscriptN/A
2023-03-06 18:38 ESTNewsRigel Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-28 01:25 ESTNewsRigel Pharmaceuticals (RIGL) Investor Presentation - SlideshowN/A
2023-01-09 20:04 ESTNewsRigel Pharma rises as preliminary Q4 revenue above estimatesN/A
2022-12-31 03:48 ESTNewsRigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023N/A
2022-12-22 20:32 ESTNewsRigel launches leukemia therapy in U.S.N/A
2022-12-15 15:09 ESTNewsRigel extends gains as dosing starts in early-stage trial for blood cancer therapyN/A
2022-12-03 04:05 ESTNewsRigel upgraded at Citi on bullish outlook for new leukemia drugN/A
2022-12-02 10:34 ESTNewsRigel stock soars 40% on FDA approval of blood cancer drug RezlidhiaN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.11 beats by $0.03, revenue of $22.4M misses by $0.21MN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Call TranscriptN/A
2022-11-02 22:35 ESTNewsRigel Pharma gains as analysts play down setback for COVID-19 therapyN/A
2022-10-31 23:15 ESTNewsRigel Pharmaceuticals Provides An Opportunity For Investors Or An AcquirerN/A
2022-10-11 06:01 ESTNewsRigel cutting 16% of workforce after declining to file sNDA for fostamatinibN/A
2022-08-18 23:47 ESTNewsRigel Pharma adds ~7% to reach over two month highN/A
2022-08-04 01:22 ESTNewsRigel rises 17% on strong Q2 resultN/A
2022-08-03 10:19 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-03 10:19 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-02 20:22 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.04, revenue of $29.82M beats by $6.17MN/A
2022-08-02 05:27 ESTNewsRigel Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-10 02:16 ESTNewsRigel Pharma downgraded at several street firms following anemia study failureN/A
2022-06-09 00:09 ESTNewsRigel stock crashes 48% as fostamatinib fails phase 3 anemia studyN/A
2022-06-09 00:08 ESTNewsRigel cut to Neutral at Cantor Fitzgerald after trial miss wipes out half of stock valueN/A
2022-05-31 10:56 ESTNewsRigel Pharmaceuticals: A Status CheckN/A
2022-05-04 11:44 ESTNewsRigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-03 19:55 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.16 misses by $0.02, revenue of $16.74M misses by $0.8MN/A
2022-05-03 19:54 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-03 01:40 ESTNewsRigel Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-08 20:19 ESTNewsRigel Pharmaceuticals grants stock options to employeesN/A
2022-03-22 02:13 ESTNewsRigel Pharmaceuticals: Why The Stock Is On A RunN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.13 in-line, revenue of $20.41M misses by $0.79MN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-02-28 17:57 ESTNewsRigel Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-01 13:56 ESTNewsRigel Pharmaceuticals: A Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety NetN/A
2022-01-11 00:53 ESTNewsRigel down as it expects slight decrease in products sales in Q4 compared to prior yearN/A
2021-12-22 03:23 ESTNewsRigel Pharma says its trial for bleeding disorder therapy met main goal in JapanN/A
2021-11-30 10:44 ESTNewsRigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects AliveN/A

About Rigel Pharmaceuticals, Inc (RIGL):

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

RIGL Quotes by TradingView

See Advanced Chart

General

  • Name Rigel Pharmaceuticals, Inc
  • Symbol RIGL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 169
  • Last Split Factor1:9
  • Last Split Date2003-06-25
  • Fiscal Year EndDecember
  • IPO Date2000-11-29
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.rigel.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 6.34
  • Price/Book (Most Recent Quarter) 20.39
  • Enterprise Value Revenue 6.22
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.02
  • Next Year EPS Estimate -$0.20
  • Next Quarter EPS Estimate -$0.03
  • Profit Margin -27%
  • Operating Margin -27%
  • Return on Assets -14%
  • Return on Equity -68%
  • Revenue 108.62 million
  • Earnings Per Share -$0.35
  • Revenue Per Share $0.64
  • Gross Profit 47.63 million
  • Quarterly Earnings Growth 19.8%
View More

Highlights

  • Market Capitalization 689.52 million
  • EBITDA -60896000
  • PE Ratio -16.62
  • PEG Ratio -0.1
  • Analyst Target Price $8.5
  • Book Value Per Share $0.20
View More

Share Statistics

  • Shares Outstanding 170.04 million
  • Shares Float 169.52 million
  • % Held by Insiders 31%
  • % Held by Institutions 85.26%
  • Shares Short 16.81 million
  • Shares Short Prior Month 19.36 million
  • Short Ratio 3.15
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.45
  • 52 Week High $5.5
  • 52 Week Low $1.26
  • 50 Day Moving Average 4.2
  • 200 Day Moving Average 3.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Rigel Pharmaceuticals, Inc (RIGL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Rigel Pharmaceuticals, Inc (RIGL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$18.45 million-$0.11-$0.113.51%
2020-09-302020-11-05$18.39 million-$0.08-$0.1234.05%
2020-06-302020-08-04$16.02 million-$0.10-$0.1426.09%
2020-03-312020-05-05$55.76 million$0.13$0.13-1.59%
2019-12-312020-02-27$15.4 million-$0.10-$0.1217.56%
2019-09-302019-11-05$20.86 million-$0.07-$0.1032.69%
2019-06-302019-08-06$10.41 million-$0.12-$0.1412.22%
2019-03-312019-05-07$12.62 million-$0.11-$0.1315.38%
2018-12-312019-02-28$37.86 million$0.02$0.03-41.35%
2018-09-302018-11-06$4.87 million-$0.14-$0.157.83%
2018-06-302018-08-08$1.79 million-$0.16-$0.16-0.19%
2018-03-312018-05-01$N/A-$0.17-$0.183.41%
2017-12-312018-03-06$3.58 million-$0.18-$0.13-35.03%
2017-09-302017-11-07$900000-$0.14-$0.158.32%
2017-06-302017-08-01$-3584000-$0.16-$0.14-12.76%
2017-03-312017-05-02$3.58 million-$0.13-$0.12-5.18%
2016-12-312017-03-07$3 million-$0.16-$0.175.33%
2016-09-302016-11-01$3.76 million-$0.24-$0.23-3.99%
2016-06-302016-08-02$8.59 million-$0.15-$0.2026.33%
2016-03-312016-05-03$5.03 million-$0.19-$0.219.18%
2015-12-312016-03-08$8.54 million-$0.14-$0.14-3.47%
2015-09-302015-11-03$13 million-$0.08-$0.1752.94%
2015-06-302015-08-04$5.18 million-$0.16-$0.2227.27%
2015-03-312015-05-07$2.18 million-$0.21-$0.18-16.67%
2014-12-312015-03-03$8.25 million-$0.15-$0.2642.31%
2014-09-302014-11-04$N/A-$0.24-$0.2711.11%
2014-06-302014-08-05$N/A-$0.29-$0.25-16%
2014-03-312014-05-07$N/A-$0.25-$0.250%
2013-12-312014-03-04$5.75 million-$0.19-$0.2524%
2013-09-302013-11-05$-1400000-$0.25-$0.2913.79%
2013-06-302013-08-06$1.4 million-$0.26-$0.3013.33%
2013-03-312013-05-07$N/A-$0.29-$0.303.33%
2012-12-312013-03-05$2.25 million-$0.30-$0.326.25%
2012-09-302012-11-06$-1500000-$0.36-$0.372.7%
2012-06-302012-08-07$1.5 million-$0.35-$0.350%
2012-03-312012-05-01$750000-$0.32-$0.31-3.23%
2011-12-312012-03-06$395000-$0.36-$0.28-28.57%
2011-09-302011-11-01$4.36 million-$0.25-$0.3016.67%
2011-06-302011-08-02$395000-$0.37-$0.382.63%
2011-03-312011-05-03$N/A-$0.40-$0.36-11.11%
2010-12-312011-03-01$52.72 million-$0.33-$0.368.33%
2010-09-302010-11-02$72.28 million$0.96$0.6254.84%
2010-06-302010-08-03$49.46 million$0.51$0.478.51%
2010-03-312010-05-04$3.26 million-$0.43$0.11-490.91%
2009-12-312010-03-02$750000-$0.48-$0.45-6.67%
2009-09-302009-11-03$N/A-$0.70-$0.58-20.69%
2009-06-302009-08-04$N/A-$0.81-$0.810%
2009-03-312009-05-05$N/A-$0.82-$0.9917.17%
2008-12-312009-02-24$N/A-$0.91-$0.976.19%
2008-09-302008-11-03$N/A-$1.03-$0.87-18.39%
2008-06-302008-08-05$N/A-$0.93-$0.69-34.78%
2008-03-312008-05-06$N/A-$0.79-$0.62-27.42%
2007-12-312008-02-12$8 million-$0.61-$0.43-41.86%
2007-09-302007-11-06$-1956000-$0.61-$0.57-7.02%
2007-06-302007-08-07$1.96 million-$0.68-$0.63-7.94%
2007-03-312007-05-10$2.64 million-$0.68-$0.67-1.49%
2006-12-312007-02-06$3.13 million-$0.62-$0.643.13%
2006-09-302006-11-07$6.13 million-$0.46-$0.472.13%
2006-06-302006-08-02$14.32 million-$0.09-$0.5683.93%
2006-03-312006-05-02$9.9 million-$0.34-$0.32-6.25%
2005-12-312006-02-07$6.02 million-$0.36-$0.4316.28%
2005-09-302005-11-08$3.28 million-$0.56-$0.618.2%
2005-06-302005-08-03$4.61 million-$0.62-$0.7112.68%
2005-03-312005-05-03$2.62 million-$0.57-$0.48-18.75%
2004-12-312005-02-08$1.1 million-$0.75-$0.69-8.7%
2004-09-302004-11-05$659000-$0.88-$0.71-23.94%
2004-06-302004-08-03$1.49 million-$0.68-$0.748.11%
2004-03-312004-05-04$1.49 million-$0.81-$0.78-3.85%
2003-12-312004-02-03$2.11 million-$0.80-$0.71-12.68%
2003-09-302003-11-05$2.1 million-$0.78
2003-06-302003-08-05$2.35 million-$1.90
2003-03-312003-05-06$4.5 million-$1.53
2002-12-312003-02-05$3.7 million-$1.62-$2.1625%
2002-09-302002-11-04$3.65 million-$1.98-$1.80-10%
2002-06-302002-08-06$4.34 million-$2.07-$1.35-53.33%
2002-03-312002-05-07$4.1 million-$1.71-$1.53-11.76%
2001-12-312002-02-05$4.78 million-$1.44-$1.8421.74%
2001-09-302001-11-07$4.21 million-$1.53-$1.530%
2001-06-302001-08-08$3.12 million-$1.80-$0.99-81.82%
2001-03-312001-05-08$3.19 million-$0.99-$1.4431.25%
2000-12-312001-02-07$3.21 million-$3.24-$2.34-38.46%

Rigel Pharmaceuticals, Inc (RIGL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Rigel Pharmaceuticals, Inc (RIGL) Chart:

Rigel Pharmaceuticals, Inc (RIGL) News:

Below you will find a list of latest news for Rigel Pharmaceuticals, Inc (RIGL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Rigel Pharmaceuticals, Inc (RIGL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-08-15100CALL0 0288.08TRUE00
2025-08-15120CALL0 0209.6TRUE00
2025-08-15130CALL0 0216.36TRUE00
2025-08-15140CALL0 0161.05TRUE00
2025-08-15150CALL0 0178.08TRUE00
2025-08-15164.3CALL0 1171.95TRUE00
2025-08-15174CALL0 3093.34TRUE00
2025-08-15183.5CALL0 5139.07TRUE00
2025-08-15191.8CALL0 1116.01TRUE00
2025-08-15201.6CALL3 3479.58TRUE-0.3-0.16
2025-08-15211.32CALL21 3487.74FALSE0.070.06
2025-08-15220.79CALL1 477.24FALSE0.790
2025-08-15231.09CALL0 10178.74FALSE00
2025-08-15240.4CALL0 8196.75FALSE00
2025-08-15250.5CALL0 2210.76FALSE00
2025-08-15260.05CALL0 1223.66FALSE00
2025-08-15270CALL0 0216.3FALSE00
2025-08-15280.46CALL0 3246.84FALSE00
2025-08-15300.2CALL0 1144.99FALSE00
2025-08-15100PUT0 0478.4FALSE00
2025-08-15120PUT0 0392.4FALSE00
2025-08-15130PUT0 0231.04FALSE00
2025-08-15140PUT0 0317.14FALSE00
2025-08-15150PUT0 0283.52FALSE00
2025-08-15161.25PUT0 1251.82FALSE00
2025-08-15170.27PUT11 1874.34FALSE0.270
2025-08-15180.6PUT0 6189.25FALSE00
2025-08-15191.45PUT1 0109.64FALSE1.450
2025-08-15200.8PUT10 1155.88FALSE0.80
2025-08-15212.6PUT0 1598.14TRUE00
2025-08-15220PUT0 0105.06TRUE00
2025-08-15230PUT0 065.22TRUE00
2025-08-15244.45PUT0 1117.06TRUE00
2025-08-15250PUT0 0110.49TRUE00
2025-08-15260PUT0 0121.62TRUE00
2025-08-15270PUT0 0128.29TRUE00
2025-08-15280PUT0 0148.92TRUE00
2025-08-15300PUT0 0142.61TRUE00
2025-09-1930CALL0 0433.37TRUE00
2025-09-1950CALL0 0332.53TRUE00
2025-09-1990CALL0 0210.19TRUE00
2025-09-191011.7CALL0 6187.32TRUE00
2025-09-19110CALL0 0143.89TRUE00
2025-09-19129.4CALL0 1138.05TRUE00
2025-09-19138CALL0 8128.02TRUE00
2025-09-19140CALL0 2136.41TRUE00
2025-09-19155CALL0 4112.59TRUE00
2025-09-19164.3CALL0 10119.02TRUE00
2025-09-19170CALL0 0104.7TRUE00
2025-09-19183.92CALL0 13105.09TRUE00
2025-09-19192.5CALL0 1979.64TRUE00
2025-09-19202.17CALL0 3085.77TRUE00
2025-09-19211.65CALL0 2199.26FALSE00
2025-09-19221.7CALL0 8292.51FALSE00
2025-09-19231.02CALL0 93106.84FALSE00
2025-09-19242.06CALL0 33111.27FALSE00
2025-09-19250.85CALL0 7682.28FALSE00
2025-09-19300.65CALL0 56122.39FALSE00
2025-09-19350.15CALL0 3795.13FALSE00
2025-09-1930PUT0 2502.29FALSE00
2025-09-1950PUT0 0546.56FALSE00
2025-09-1990PUT0 2326.04FALSE00
2025-09-19100PUT0 0292.88FALSE00
2025-09-19110PUT0 0263.77FALSE00
2025-09-19120.35PUT0 1237.73FALSE00
2025-09-19130PUT0 2193.83FALSE00
2025-09-19140.65PUT0 1173.51FALSE00
2025-09-19150.95PUT0 27121.66FALSE00
2025-09-19161.66PUT0 2142.73FALSE00
2025-09-19170.65PUT1 564.49FALSE0.650
2025-09-19181.95PUT0 1889.88FALSE00
2025-09-19192.8PUT0 2696.3FALSE00
2025-09-19202PUT1 669.16FALSE20
2025-09-19210PUT0 080.64TRUE00
2025-09-19220PUT0 071.53TRUE00
2025-09-19230PUT0 076.75TRUE00
2025-09-19240PUT0 084.93TRUE00
2025-09-19256.6PUT0 1100.02TRUE00
2025-09-19300PUT0 099.56TRUE00
2025-09-19350PUT0 0138.83TRUE00
2025-12-1930CALL0 0263.12TRUE00
2025-12-1950CALL0 1205.27TRUE00
2025-12-1990CALL0 0127.85TRUE00
2025-12-19109.8CALL0 2108.41TRUE00
2025-12-19110CALL0 0102.9TRUE00
2025-12-19128.2CALL0 2108.59TRUE00
2025-12-19137.71CALL0 399.84TRUE00
2025-12-19140CALL0 099.09TRUE00
2025-12-19156CALL0 591.8TRUE00
2025-12-19160CALL0 1287.12TRUE00
2025-12-19174.9CALL0 496.35TRUE00
2025-12-19180CALL0 169.98TRUE00
2025-12-19195.21CALL0 666.72TRUE00
2025-12-19203.6CALL0 3587.4TRUE00
2025-12-19210CALL0 272.05FALSE00
2025-12-19222.49CALL0 2873.32FALSE00
2025-12-19232.39CALL0 14185.18FALSE00
2025-12-19242.65CALL0 159.84FALSE00
2025-12-19251.75CALL0 5261.42FALSE00
2025-12-19262.85CALL0 285.44FALSE00
2025-12-19271.95CALL0 084.42FALSE00
2025-12-19280CALL0 196.7FALSE00
2025-12-19290CALL0 092.54FALSE00
2025-12-19301.15CALL1 2569.87FALSE1.150
2025-12-19350.6CALL0 167.14FALSE00
2025-12-1930PUT0 0552.79FALSE00
2025-12-1950PUT0 0263.71FALSE00
2025-12-1990.7PUT0 2202.02FALSE00
2025-12-19100.8PUT0 2142.57FALSE00
2025-12-19110.95PUT0 3137.66FALSE00
2025-12-19120PUT0 1130.68FALSE00
2025-12-19130PUT0 2115.84FALSE00
2025-12-19141.35PUT0 1109.61FALSE00
2025-12-19151.75PUT0 2107.36FALSE00
2025-12-19161.9PUT0 295.64FALSE00
2025-12-19172.53PUT0 492.17FALSE00
2025-12-19182.94PUT0 380.39FALSE00
2025-12-19193.43PUT0 1265.74FALSE00
2025-12-19200PUT0 159.53FALSE00
2025-12-19210PUT0 064.08TRUE00
2025-12-19220PUT0 070.56TRUE00
2025-12-19230PUT0 070.8TRUE00
2025-12-19240PUT0 071.34TRUE00
2025-12-19250PUT0 065.61TRUE00
2025-12-19260PUT0 072.63TRUE00
2025-12-19270PUT0 078.29TRUE00
2025-12-19280PUT0 077.27TRUE00
2025-12-19290PUT0 080.18TRUE00
2025-12-19300PUT0 079.42TRUE00
2025-12-19350PUT0 082.54TRUE00
2026-03-2050CALL0 0158.7TRUE00
2026-03-20100CALL0 0111.79TRUE00
2026-03-20110CALL0 094.87TRUE00
2026-03-20120CALL0 095.81TRUE00
2026-03-20138.31CALL0 390.48TRUE00
2026-03-20140CALL0 084TRUE00
2026-03-20150CALL0 078.81TRUE00
2026-03-20160CALL0 079.63TRUE00
2026-03-20170CALL0 073.04TRUE00
2026-03-20180CALL0 074.54TRUE00
2026-03-20190CALL0 071.03TRUE00
2026-03-20206.4CALL0 268.05TRUE00
2026-03-20210CALL0 069.87FALSE00
2026-03-20220CALL0 071.91FALSE00
2026-03-20230CALL0 071.51FALSE00
2026-03-20240CALL0 068.79FALSE00
2026-03-20250CALL0 070.32FALSE00
2026-03-20260CALL0 070.34FALSE00
2026-03-20270CALL0 071.21FALSE00
2026-03-20300CALL0 078.27FALSE00
2026-03-20350CALL0 087.98FALSE00
2026-03-2050PUT0 0267.34FALSE00
2026-03-20100PUT0 0110.46FALSE00
2026-03-20111.05PUT0 1100.81FALSE00
2026-03-20121.25PUT0 1101.02FALSE00
2026-03-20130PUT0 095.86FALSE00
2026-03-20140PUT0 095.29FALSE00
2026-03-20150PUT0 085.52FALSE00
2026-03-20160PUT0 075.83FALSE00
2026-03-20170PUT0 073.67FALSE00
2026-03-20183.2PUT0 271.51FALSE00
2026-03-20190PUT0 067.65FALSE00
2026-03-20200PUT0 063.47FALSE00
2026-03-20210PUT0 066.46TRUE00
2026-03-20220PUT0 073.51TRUE00
2026-03-20230PUT0 059.36TRUE00
2026-03-20240PUT0 064.99TRUE00
2026-03-20250PUT0 064.76TRUE00
2026-03-20260PUT0 067.29TRUE00
2026-03-20270PUT0 071.9TRUE00
2026-03-20300PUT0 072.96TRUE00
2026-03-20350PUT0 077.41TRUE00

Latest RIGL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$0.6924
Jun 13, 2022 7:59 PM EST200$0.6924
Jun 13, 2022 7:59 PM EST100$0.6924
Jun 13, 2022 7:59 PM EST500$0.6924
Jun 13, 2022 7:59 PM EST850$0.6921

Rigel Pharmaceuticals, Inc (RIGL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm
2019-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000021545719005836/0000215457-19-005836-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000031506619001306/0000315066-19-001306-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000031506620001146/0000315066-20-001146-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000083423720006820/0000834237-20-006820-index.htm
2020-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000083423720009960/0000834237-20-009960-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000090221919000369/0000902219-19-000369-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000090221920000160/0000902219-20-000160-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000093041319000568/0000930413-19-000568-index.htm
2019-04-09DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1034842/000104746919002080/0001047469-19-002080-index.htm
2020-04-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1034842/000104746920001990/0001047469-20-001990-index.htm
2020-05-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000104746920002759/0001047469-20-002759-index.htm
2020-08-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1034842/000104746920004389/0001047469-20-004389-index.htm
2018-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918034498/0001104659-18-034498-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918037232/0001104659-18-037232-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918050532/0001104659-18-050532-index.htm
2018-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465918050560/0001104659-18-050560-index.htm
2018-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918060459/0001104659-18-060459-index.htm
2018-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918064285/0001104659-18-064285-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918066323/0001104659-18-066323-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919001118/0001104659-19-001118-index.htm
2019-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919002845/0001104659-19-002845-index.htm
2019-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919005217/0001104659-19-005217-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919011582/0001104659-19-011582-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919017440/0001104659-19-017440-index.htm
2019-04-09DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000110465919020480/0001104659-19-020480-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919027507/0001104659-19-027507-index.htm
2019-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919029862/0001104659-19-029862-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919031798/0001104659-19-031798-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919044305/0001104659-19-044305-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465919044376/0001104659-19-044376-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919052388/0001104659-19-052388-index.htm
2019-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919055689/0001104659-19-055689-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919060054/0001104659-19-060054-index.htm
2019-11-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919065084/0001104659-19-065084-index.htm
2019-11-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919066635/0001104659-19-066635-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919073467/0001104659-19-073467-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920003446/0001104659-20-003446-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000110465920016449/0001104659-20-016449-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920026180/0001104659-20-026180-index.htm
2020-04-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000110465920041947/0001104659-20-041947-index.htm
2020-05-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920056879/0001104659-20-056879-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920062621/0001104659-20-062621-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920090262/0001104659-20-090262-index.htm
2020-08-04S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465920090388/0001104659-20-090388-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920113467/0001104659-20-113467-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920121776/0001104659-20-121776-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006680/0001179110-18-006680-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006681/0001179110-18-006681-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006682/0001179110-18-006682-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007148/0001179110-18-007148-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007149/0001179110-18-007149-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007150/0001179110-18-007150-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007151/0001179110-18-007151-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007152/0001179110-18-007152-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007153/0001179110-18-007153-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007154/0001179110-18-007154-index.htm
2018-06-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018008174/0001179110-18-008174-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018008176/0001179110-18-008176-index.htm
2018-07-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm
2018-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010636/0001179110-18-010636-index.htm
2018-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm
2018-08-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm
2018-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000931/0001179110-19-000931-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000932/0001179110-19-000932-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000933/0001179110-19-000933-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000934/0001179110-19-000934-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000935/0001179110-19-000935-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000936/0001179110-19-000936-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000938/0001179110-19-000938-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000939/0001179110-19-000939-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000940/0001179110-19-000940-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004205/0001179110-19-004205-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004206/0001179110-19-004206-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004207/0001179110-19-004207-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004208/0001179110-19-004208-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004209/0001179110-19-004209-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004210/0001179110-19-004210-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004211/0001179110-19-004211-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004212/0001179110-19-004212-index.htm
2019-04-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004736/0001179110-19-004736-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004740/0001179110-19-004740-index.htm
2019-05-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006694/0001179110-19-006694-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006698/0001179110-19-006698-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006699/0001179110-19-006699-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006700/0001179110-19-006700-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006701/0001179110-19-006701-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006702/0001179110-19-006702-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006703/0001179110-19-006703-index.htm
2019-11-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011701/0001179110-19-011701-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011937/0001179110-19-011937-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011938/0001179110-19-011938-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011940/0001179110-19-011940-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011942/0001179110-19-011942-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011944/0001179110-19-011944-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011946/0001179110-19-011946-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011948/0001179110-19-011948-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001348/0001179110-20-001348-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001349/0001179110-20-001349-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001350/0001179110-20-001350-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001351/0001179110-20-001351-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006129/0001179110-20-006129-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006130/0001179110-20-006130-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006131/0001179110-20-006131-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006132/0001179110-20-006132-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006133/0001179110-20-006133-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006134/0001179110-20-006134-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006135/0001179110-20-006135-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm
2020-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020009204/0001179110-20-009204-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020009207/0001179110-20-009207-index.htm
2019-11-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000131924419000084/0001319244-19-000084-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000131924420000054/0001319244-20-000054-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837018006758/0001558370-18-006758-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837018008624/0001558370-18-008624-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1034842/000155837019001310/0001558370-19-001310-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019004244/0001558370-19-004244-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019007232/0001558370-19-007232-index.htm
2019-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019009974/0001558370-19-009974-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1034842/000155837020001624/0001558370-20-001624-index.htm
2020-05-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020005179/0001558370-20-005179-index.htm
2020-08-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020009154/0001558370-20-009154-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020012838/0001558370-20-012838-index.htm
2019-03-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999719001548/9999999997-19-001548-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000137/9999999997-20-000137-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000138/9999999997-20-000138-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000139/9999999997-20-000139-index.htm
2020-02-05SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000517/9999999997-20-000517-index.htm
2020-02-18SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000741/9999999997-20-000741-index.htm
2020-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720002114/9999999997-20-002114-index.htm
2020-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720002115/9999999997-20-002115-index.htm

Rigel Pharmaceuticals, Inc (RIGL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rigel Pharmaceuticals, Inc (RIGL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 31%
Institutional Ownership: 8526%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-07-02Anne-Marie DuliegeEVP & Chief Medical OfficerSell5,000.002.7913,932.000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm
2018-09-04Anne-Marie DuliegeEVP & Chief Medical OfficerSell16,500.003.5157,860.550.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerSell115,500.003.50404,250.000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-08-23Eldon C. III MayerEVP & Chief Commercial OfficerBuy100,000.002.82282,320.00115,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerBuy115,500.002.54293,370.00115,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-09-04Anne-Marie DuliegeEVP & Chief Medical OfficerBuy16,500.002.5441,910.0016,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-10Eldon C. III MayerEVP & Chief Commercial OfficerBuy50,000.003.28164,210.00165,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-08-17RAUL R RODRIGUEZCEO, PresidentBuy114,000.002.63300,002.40173,519.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm
2018-09-11Eldon C. III MayerEVP & Chief Commercial OfficerBuy50,000.003.23161,340.00215,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerBuy37,500.002.1179,125.0037,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2019-05-22Dean L SchornoEVP &Chief Financial OfficerBuy46,726.002.1399,573.1146,726.00https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2019-05-22Dean L SchornoEVP &Chief Financial OfficerBuy3,274.002.136,971.0050,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2018-10-12Nelson CabatuanPrincipal Accounting OfficerSell10,000.003.1231,200.0058.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm